Practical guidelines for treating inflammatory bowel disease safely with anti-tumour necrosis factor therapy in Australia

Simple item page
dc.contributor.authorConnell, W.
dc.contributor.authorAndrews, J.
dc.contributor.authorSparrow, M.
dc.date.issued2010
dc.description.abstractAnti-tumour necrosis factor (TNF) therapy is an effective but expensive option for treating inflammatory bowel disease (IBD). Its use is generally reserved for patients with severe refractory disease, often involving long-term administration. Anti-TNF therapy has the potential to be associated with various adverse effects, such as infection, malignancy and immunogenicity. Clinicians and patients should be familiar with these possibilities and adopt appropriate precautions prior to and during treatment to minimize risk. Guidelines have been developed for Australian prescribers intending to use anti-TNF therapy in IBD by a Working Party commissioned by IBD-Australia, a Special Interest Group affiliated with the Gastroenterology Society of Australia.
dc.description.statementofresponsibilityW. Connell, J. M. Andrews, S. Brown and M. Sparrow
dc.identifier.citationInternal Medicine Journal, 2010; 40(2):139-149
dc.identifier.doi10.1111/j.1445-5994.2009.02122.x
dc.identifier.issn1444-0903
dc.identifier.issn1445-5994
dc.identifier.orcidAndrews, J. [0000-0001-7960-2650]
dc.identifier.urihttp://hdl.handle.net/2440/61276
dc.language.isoen
dc.publisherBlackwell Publishing Asia
dc.rights© 2010 The Authors. Journal compilation © 2010 Royal Australasian College of Physicians
dc.source.urihttps://doi.org/10.1111/j.1445-5994.2009.02122.x
dc.subjectCrohn’s disease
dc.subjectanti TNF therapy
dc.subjectadalimumab
dc.subjectinfliximab
dc.subjectulcerative colitis
dc.subjectguidelines.
dc.titlePractical guidelines for treating inflammatory bowel disease safely with anti-tumour necrosis factor therapy in Australia
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Medicine publications